Association of intracellular lipid accumulation in subcutaneous adipocyte precursors and plasma adipokines in bariatric surgery candidates

Ioana Hristov¹, Veronica Mocanu*, Florin Zugun-Eloae¹,², Luminita Labusca³, Iustina Cretu-Silivestru¹, Teodor Oboroceanu¹, Crina Tiron², Adrian Tiron², Alexandra Burlacu⁴, Alin Constantin Pinzariu¹, Ioana Armasu¹, Radu Mircea Neagoe⁵, Adrian Covic¹,⁶, Viorel Scripcariu¹ and Daniel Vasile Timofte¹

Abstract

Background: The adipocyte expansion is a critical process with implications in the pathogenesis of obesity associated metabolic syndrome. Impaired adipogenesis leads to dysfunctional, hypertrophic adipocytes, local inflammation and peripheric insulin resistance.

Methods: We assessed the relationship between the adipogenic differentiation capacity of the subcutaneous adipose derived stem cells (ASCs), evaluated by total lipid accumulation, and the metabolic and hormonal profile in a group of obese female patients proposed for bariatric surgery (N = 20) versus normal weight female controls (N = 7).

Results: The lipid accumulation (measured as optical density at 492 nm) of ASCs during their differentiation to adipocytes was significantly lower in ASCs isolated from obese patients as compared to ASCs isolated from normal weight patients (0.49 ± 0.1 vs. 0.71 ± 0.1, p < 0.001). Significant negative correlations between lipid accumulation in adipogenic differentiated ASCs and plasma concentrations of triglycerides (p < 0.01), insulin (p < 0.001), HOMA-IR (p < 0.01), adiponectin (p < 0.05) and leptin/adiponectin ratio (p < 0.05) were found in obese group.

Conclusions: In severely obese female patients, the abnormal adipogenesis is related to insulin resistance and leptin/adiponectin ratio. The abnormal lipid accumulation in the mature adipocyte derived from obese ASCs could possibly predict the further development of type 2 diabetes mellitus in severely obese patients and influence the selection of patients for bariatric surgery.

Keywords: Adipocyte differentiation, Subcutaneous adipose derived stem cells, Obesity, Metabolic syndrome, Insulin resistance, Leptin/adiponectin ratio, Metabolic surgery

Background

The obese individuals are reportedly at high risk for cardio-metabolic diseases. As the metabolic syndrome is an important predictor, not only for cardiovascular mortality but also for all-cause mortality, the evaluation of the metabolic status of the obese patients needs to be performed precociously and by accurate methods [1].

* Correspondence: veronica.mocanu@umfiasi.ro

¹Grigore T. Popa* University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania

Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
disturbances [5], and the particularities of adiposity expansion in the obese patients in not understood.

Insulin resistance is closely associated with disturbances of fat metabolism [6]. Thus, exceeding the storage capacity of the subcutaneous adipose tissues results in lipotoxicity, a condition characterized by fatty acid infiltration of insulin target tissues i.e., skeletal muscle and liver, that eventually leads to insulin resistance [6].

High leptin levels and leptin:adiponectin ratio are predictors of obesity-related complications as type 2 diabetes mellitus (T2DM) and hypertension independent of BMI or the metabolic syndrome (MetS) criteria [7–9]. The subcutaneous fat mass expansion is initiated by adipocyte hyperplasia, a physiological process that generates new mature adipose cells through activation and differentiation of multipotent stem progenitors. However, increasing expansion requirements eventually exceeds the individual adipogenic differentiation capacity of preadipocytes. When this adipogenic potential is reached, excessive lipid accumulation results in a dysfunctional adipose tissue [10–14], due to adipocyte hypertrophy, decreased adipogenesis and angiogenesis [15,16].

Subcutaneous adipose tissue consists predominantly of adipocytes, but also contains other cell populations generally referred to as the stromal vascular fraction (SVF). Zuk et al. [17] identified in the SVF, a multipotent, undifferentiated, self-renewing progenitor cell population that is morphologically and phenotypically like mesenchymal stem cells (MSCs). These isolated adipose tissue-derived stem cells (ASCs) display a capacity of differentiation like MSCs and show the expression of the specific stem cell markers in vivo [18]. ASCs however have a series of advantages as a multipotent differentiation source as they are more accessible by simple subcutaneous adipose tissue biopsy, a repeatable minimally invasive method, the isolation procedure is simple and the stem cell quality and proliferation capacity that does not decline with the age of the patient [19]. After isolation and proliferation of these ASCs, they can be used for experimental study of the molecular processes in regulating adipocyte differentiation [20].

Previous studies evaluated the changes induced by obesity in the adipogenic differentiation of ASCs with controversial results: from enhanced [21,22], unchanged [23] to decreased adipogenesis [24–27]. This could be attributed to ASCs isolated from obesity donors with distinct stages of obesity, different ages, as well as with or without metabolic dysfunction.

The aim of our experimental study was to assess the adipogenic capacity of subcutaneous ASCs in obese female patients prior to bariatric surgery in relation to plasma metabolic and hormonal parameters.

Materials and methods
Characteristics of the study group
The study included 20 obese female patients (OB group), referred for Laparoscopic Sleeve Gastrectomy (LSG) and seven normal weight females (NW group, control) with other abdominal surgery indications. The mean body mass index (BMI) was 45.02 ± 6.31 kg/m² in OB group and 24.46 ± 2.50 kg/m² in NW group. The age ranges of the two groups matched, with a mean of 42.05 ± 9.91 years for OB group and 42.00 ± 10.67 years for the NW group.

Biochemical measurements
Blood samples were collected after 12 h of fast, before the bariatric surgery procedure. The lipid profile was established based on the following serum determinations: Fasting plasma glucose (FPG), Total Cholesterol (TC), Low Density Lipoproteins (LDL) Cholesterol, High Density Lipoproteins (HDL) Cholesterol, Triglycerides (TG) and TC/HDL ratio. Plasma concentrations of insulin and total morning cortisol (8:00 a.m) were measured using electrochemiluminescence immunoassay method. HOMA-IR was calculated using the formula: $\text{HOMA-IR} = \frac{\text{FPG} \times \text{FPI}}{\text{405} \times \text{FPG}}$, where FPG = fasting plasma glucose (mg/dl), FPI = fasting plasma insulin (μIU/ml) and FPG = fasting plasma glucose (mg/dl). Leptin and adiponectin was measured in plasma using ELISA method (Sigma Aldrich kit RAB0005 was used for adiponectin and Fine Test EH0216 for leptin serum concentration quantification).

ASCs isolation and proliferation
ASC culture was derived using a protocol described by Lyons [26], starting from a small amount of subcutaneous abdominal adipose tissue (less than 1 g) remained in the trocar during the laparoscopic procedure, so that to not create supplemental patient discomfort to the bariatric surgery procedure. The sample was washed in 0.9% saline solution and digested in 10 mg/ml collagenase type I (Sigma Aldrich lot # SLBM2283V) for 15 min. Dulbecco’s modified Eagle’s medium (DMEM)/F12. The washed digested tissue was subjected to red blood cells lysis and released cells were passed through a 70 μm cell strainer before being re-suspended at a density of 1.5 × 10⁵ cells/ml culture medium (DMEM/F12 + 10% foetal bovine serum (FBS),100 U/ml penicillin and 100 μg/ml streptomycin). Cells were cultured at 37 °C under 5% CO₂ atmosphere and the medium was refreshed every 2–3 days. Progression towards ASCs confluence was followed for a medium duration of 16 ± 3 days using an inverted optical microscope (Olympus CKXC3).

Adipogenic differentiation
The 80–90% confluent ASCs are incubated in an adipogenic induction medium containing: DMEM/F12, 10%FBS, 0.5 mM IBMX, 1% ITS (Insulin Transferrin Selenite, Sigma
some proliferator activated receptor gamma, PPARγ specific markers, immunofluorescence staining for peroxisomal activation values at 492 nm wavelength (OD492), after elution of ORO-stained cells in 90% isopropanol. Absorbance values for each plate expressed the lipid accumulation quantification.

Immunofluorescence analysis
To evaluate the mesenchymal features of the cells, a monoclonal anti-vimentin antibody (Cell Signaling Tech, D21H3) coupled with Alexa Fluor® 488 was used for immunofluorescent labelling of control and differentiated cells. To these aims, cells were permeabilized in Triton X100 (0.1% in PBS) and incubated with the antibodies, as previously described [27]. To identify the adipocyte specific markers, immunofluorescence staining for peroxisome proliferator activated receptor gamma, PPARγ (Cell Signaling Tech, 2435S) and perilipin (Thermo Fisher Scientific, PA5–18694) will be performed on differentiated ASCs. At the end of the procedures, the stained cells were washed and evaluated under a fluorescent microscope Zeiss Axio Observer Z1 microscope. DAPI (Sigma, D9542) was used to stain cell nuclei.

Statistical analysis
Data were analysed using IBM SPSS Statistics 21 Software and expressed as mean (±standard deviation) and median (min-max) values. Comparisons between parameters in obese patients and normoponderal control were performed using the Mann–Whitney test. Kendall’s Tau-b correlation coefficient, a nonparametric measure, was computed to evaluate correlations between lipid accumulation evaluation and biochemical and hormonal parameters. Significance was defined as p < 0.05.

Results and discussion
Characteristics of patients
Plasma concentrations of total cholesterol, LDL-cholesterol, triglycerides, fasting glucose, insulin, C-peptide and metabolic indices (HOMA-IR and total cholesterol/HDL-cholesterol) were significantly increased in OB group as compared with NW group. Significantly higher plasma concentrations of leptin and leptin/adiponectin ratio values were found in OB group as compared with NW group. No significant differences were obtained for plasma morning cortisol and adiponectin (Table 1).

Adipose derived stem cell (ASCs) isolation, proliferation and differentiation
The stromal fractions were obtained from subcutaneous abdominal adipose tissue derived from OB and NW group and grown in culture at a starting density of 1.5 × 10³ cells/ml.

The ASCs proliferation to confluence was obtained after 18 ± 4 days for OB patients isolated ASCs and after 16 ± 3 days for ASCs in NW patients, with no statistically significant difference between OB and NW groups.

The cell culture viability was evaluated by MTT-formazan (3, 4, 5-dimethylthiazol-2,5-diphenyltetrazolium bromide) according to the protocol of Mossman et al. [28]. The metabolic activity of mesenchymal stem cells evaluated using MTT assay was 93 ± 3% for the OB group with a similar result: 94 ± 2% for the control NW group.

Identification of mesenchymal specific markers
In our study, in order to characterize the cell culture population as mesenchymal stem cells, we evaluated the expression of vimentin (Fig. 1).

Differentiation of subcutaneous ASCs and intracellular lipid accumulation (oil red O staining)
Adipogenic differentiation protocol was monitored in cell cultures using optic microscopy and lipid accumulation was observed from day 10 ± 3 in NW samples and from day 12 ± 4 in OB. We observed fewer perilipin-positive (viable adipocytes) cells in OB samples as compared to NW samples (Fig. 2).

Specific lipid stain was evaluated using ORO and the lipid accumulation obtained for adipocytes differentiated from NW (Fig. 3). The lipid droplets accumulated were fewer and smaller in the OB samples. ORO absorbance at 492 nm by spectrophotometry showed a significant increase (p < 0.001) in lipid deposition in ASCs derived from obese patients as compared to normal weight patients (Table 1).

Correlation of lipid accumulation with metabolic parameters
Significant negative correlations were found between the lipid accumulation (OD492) and plasma triglycerides \( (r = -0.42, p < 0.01) \), insulin \( (r = -0.52, p < 0.001) \), HOMA-IR \( (r = -0.49, p < 0.01) \), adiponectin \( (r = 0.32, p < 0.05) \), and leptin/adiponectin ratio \( (r = -0.36, p < 0.05) \) (Table 2).
Table 1 Characteristics of the obese patients and normal weight controls. The data are presented as the mean (± standard deviations) and median (min-max) values.

| Parameter                        | Normal weight controls (N = 7) | Obese patients (N = 20) | P-value |
|----------------------------------|--------------------------------|-------------------------|---------|
| Age (years)                      | 42.0 (10.7)/42.0 (25–58)       | 42.1 (9.9)/45.5 (23–63) | 0.978   |
| BMI (kg/m²)                      | 24.5 (2.5)/24.7 (21.2–29.0)    | 45.0 (6.3)/43.7 (36.4–58.9) | < 0.001 |
| Lipid profile:                   |                                |                         |         |
| Total cholesterol (TC)(mg/dl)    | 166.7 (18.3)/159.0 (151–202)   | 210.6 (32.1)/212.5 (138–265) | 0.006   |
| LDL-cholesterol (LDL)(mg/dl)     | 90.0 (2.8)/90.0 (86–93)        | 141.0 (29.0)/139.5 (80–184) | 0.001   |
| HDL-cholesterol (HDL)(mg/dl)     | 54.2 (3.7)/54.0 (48–59)        | 49.7 (1.2)/49.0 (23–75)  | 0.223   |
| TC/HDL (Normal< 4)               | 3.1 (0.3)/3.1 (2.7–3.4)        | 4.4 (1.0)/3.1–6.2        | 0.001   |
| Triglycerides (TG) (mg/dl)       | 96.3 (14.4)/93.0 (73–115)      | 165.3 (103.5)/140.5 (69–448) | 0.025   |
| Glucose homeostasis:             |                                |                         |         |
| Fasting plasma glucose (mg/dl)   | 86.9 (8.9)/87.0 (73–99)        | 126.8 (74.1)/102.0 (77–362) | 0.012   |
| Insulin (µIU/ml)                 | 7.4 (1.6)/6.89 (6.3–10.7)      | 16.8 (9.1)/15.8 (6.0–43.4) | 0.003   |
| C-peptide (ng/ml)                | 1.6 (0.3)/1.5 (1.2–2.1)        | 3.2 (1.0)/3.5 (1.2–4.9)  | 0.013   |
| HOMA-IR                          | 1.6 (0.4)/1.5 (1.3–2.5)        | 6.1 (7.0)/3.8 (1.4–28.7) | 0.001   |
| Plasma hormones                  |                                |                         |         |
| Morning Cortisol (µg/dl)         | 10.1 (3.7)/9.6 (6.2–15.6)      | 12.9 (4.1)/12.4 (7.6–23.4) | 0.072   |
| Leptin (ng/dl)                   | 5.7 (2.0)/6.0 (2.8–8.0)        | 26.5 (8.8)/27.6 (8.0–39.6) | < 0.001 |
| Adiponectin (µg/dl)              | 30.6 (2.0)/30.9 (2.7–3.4)      | 29.0 (3.2)/29.1 (1.9–3.3) | 0.166   |
| Leptin: Adiponectin Ratio        | 0.18 (0.7)/1.9 (0.9–2.7)       | 0.93 (0.3)/1.0 (2.6–14.4) | < 0.001 |
| Adipocyte differentiation dysfunction | 0.71 (0.1)/0.75 (0.50–0.82) | 0.49 (0.6)/0.48 (0.41–0.67) | < 0.001 |

P-values were assessed by Mann–Whitney test to compare non-normal distributed variables. P-value ≤ 0.05 was considered significant.

**Fig. 1** ASCs characterisation as mesenchymal cells using Vimentin IF stain. Merge image cytosolic Vimentin (green) and nuclear DAPI (blue). **a.** Normoponderal ASCs. **b.** Obese ASCs.
Discussion

The altered lipid accumulation capacity of subcutaneous preadipocytes in obese patients is currently being evaluated as a precocious marker for insulin resistance as it translates the incapacity of the mesenchymal cell line progenitors to differentiate mature, functional adipocytes with optimal lipid storage capacity. Several studies found that lipid accumulation evaluates the expansion capacity of the pre-adipogenic mesenchymal cell line and is associated with a poor metabolic profile for obese patients [24, 29–31].

The subcutaneous adipose tissue represents 90% of total fat mass, it has potential to greatly affect systemic insulin resistance via adipokine secretion, that plays an important role in glucose uptake impairment, as chemerin was reported to be associated positively with BMI and the markers of inflammation and metabolic syndrome in humans [22]. Adiponectin expression has been demonstrated to accelerate 3T3-L1 proliferation and also lipid accumulation evaluated by Oil red O staining was found to be 4-fold greater in adipogenic differentiated pre-adipocytes.

Fig. 2 Immunostaining of adipogenic differentiated adipose-derived stem/stromal cells (ASCs) from NW (a) and obese (b) patients. Merge image of PPARγ (green), perilipin (yellow) and DAPI (blue)

Fig. 3 Specific lipid stain with ORO brightfield optic microscopy. a. Adipocytes differentiated from NW ASCs. b. Adipocytes differentiated from OB ASCs
that overexpressed adiponectin [32]. Also, in animal studies on mice the same results were found [33]. These results support the role of adiponectin as a key autocrine/paracrine factor that could play an essential role in the regulation of adipocyte metabolism and adipose tissue mass.

We report a decreased lipid accumulation capacity for adipogenic differentiated ASCs of obese female patients versus those from normal weight controls, and significant correlations between the adipocyte fat accumulation potential and insulin, adiponectin, leptin/adiponectin ratio (LAR).

In our study we did not find different levels of morning cortisol for obese patients and normoponderal controls. Also, there was no statistically significant correlation with lipid accumulation, showing that morning cortisol is not a valuable predictor for adipogenesis dysfunctions in obese patients. Literature data are inconsistent in this matter, some data suggest that glucocorticoids (GC) increase the lipid turnover in adipose tissue [34], but despite the major impact of GC on adipogenesis, normal or low circulating cortisol values are found in obese patients studies [35].

The fact that obesity alters the adipogenic differentiation capability of ASCs from subcutaneous adipose depots is supported by the data from other research groups [27, 36, 37]. De Girolamo et al. evaluated the ASCs adipogenic potential in obese versus non-obese controls and they also found a reduced proliferative rate for obese ASCs [31]. Alteration of the pre-adipocytes lineage in obese bariatric patients was also demonstrated by Perez et al. [37] that showed an altered lipid accumulation in obese-ASCs derived adipocytes as compared to adipocytes lineage coming from normal weight humans or mice. In another study, Perez et al. reported a significantly enhanced apoptosis and a reduced proliferative capacity of ASCs isolated from obese subjects; the impaired adipogenesis was correlated with the in vivo environmental obesity-related altered mitochondrial biogenesis, increased reactive oxygen species production and increased extracellular acidification [38].

We demonstrated that plasma insulin is correlated with decreased adipocyte ability to accumulate lipids. Previous research data published by Weyer et al., also show that the pre-adipocytes differentiation potential is correlated with insulin resistance in humans, in both obese and normal weight individuals [36]. Reported data from in vitro studies confirmed the decrease in the adipogenic differentiation ability of the ASCs from obese subjects and have described the mechanisms of obesity induced adipose-tissue remodeling, that include a disproportionate synthesis of extracellular matrix components [39] but also a decreasing number of adipocytes [40]. Thus, the variations in adipose cellularity that occur during the development of insulin resistance seem to determine a decrease in the clonogenic and proliferative potential of ASCs. Their role in unhealthy adipose tissue expansion associated with metabolic syndrome is an important predictor for obesity associated co-morbidities.

The novel finding in our study was the negative correlation between adipogenic potential (assessed by lipid accumulation in mature adipocytes) with triglycerides and LAR as key markers of impaired metabolic profile. These results point to abnormal adipogenesis as a link between obesity and its clinical complications.

Overall strengths of our study include direct measurement of the lipid accumulation in differentiated ASCs and the assessment of the relation between impaired adipogenesis with plasma metabolic and adipokine parameters in females with increased adiposity. A limitation of our study is the small size of the study and control groups and the relatively young age of the patients.

**Conclusions**

Our study demonstrates that in severely obese female patients, the ASCs from subcutaneous adipose tissue have a decreased potential for adipogenesis as compared with normal weight controls. The abnormal lipid accumulation in the mature adipocyte derived from obese ASCs could possible predict the further metabolic changes and influence the selection of patients for bariatric surgery.

**Abbreviations**

ASCs: Adipose derived stem cells; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; LSG: Laparoscopic Sleeve Gastrectomy; MSCS: Mesenchymal stem cells; PPARγ: Peroxisome proliferator-activated receptor gamma; SVF: Stromal vascular fraction
Acknowledgements
Not applicable.

Authors’ contributions
Study design and concept: VM, DVT, FZE, LL. Performance of experiment: IH, DVT, LL, ISC, CT, AT, TO, IA. Data collection and analysis: IH, VM, TO, ISC, CT, AT, AB, IA. Writing of manuscript: DVT, IH, VM, RMN, FZE, LL. Revising the manuscript: AC and VS. All authors read and approved the final manuscript.

Funding
This research received financial support from “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania, through the grants Ideas-Teams contract (29032/28.12.2016 and 30340/28.12.2017).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was performed in accord with the ethical standards of the Declaration of Helsinki and were approved by the Ethic Committee of “Grigore T. Popa” University of Medicine and Pharmacy, Iasi. Informed consent was obtained from all individual participants included in the study.

Consent for publication
Written informed consent was obtained from all participants.

Competing interests
The authors declare that they have no competing interests.

Author details
1 “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania. 2 TRANSCEND Research Center, Regional Institute of Oncology, Iasi, Romania. 3 Stem Cell Laboratory, National Institute of Research and Development for Technical Physics (NIRDTP), Iasi, Romania. 4 Nicolae Simionescu Institute of Cellular Biology and Pathology of the Romanian Academy, Bucharest, Romania. 5 University of Medicine, Pharmacy, Sciences and Technology, Tg Mures, Romania. 6 Academy of Medical Sciences, Bucharest, Romania.

Received: 9 March 2019 Accepted: 4 June 2019
Published online: 13 June 2019

References
1. Hiramori GM, Czernichow S, Dugravel A, Batty GD, Kivimaki M, Singh-Manoux A. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care. 2013;36(8):2294–300. https://doi.org/10.2337/dci12-1654.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Lotta CM, Smith SC Jr, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International association for the study of obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.
3. Morgow-Chaffin M, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, Ouyang P, Sibley CT, Tracy R, Woodward M, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71(17):1857–65. https://doi.org/10.1016/j.jacc.2018.02.055.
4. Meijs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D’Agostino RB. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906–12. https://doi.org/10.1210/jc.2006-0594.
5. Lin H, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: a PRISMA-compliant article. Medicine (Baltimore). 2017;96(47):e8838. https://doi.org/10.1097/MD.
6.50000000000008838
6. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic fat in the metabolic syndrome. Endocrinology. 2003;144(12):5159–65. https://doi.org/10.1210/en.2003-0870.
7. Kim C, Park J, Park J, Kang E, Ahn C, Cha B, Lim S, Kim K, Lee H. Comparison of body fat composition and serum adiponectin levels in diabetic obesity and non-diabetic obesity. Obesity (Silver Spring). 2006;14(7):1164–71. https://doi.org/10.1081/oby.20063133.
8. Rueda-Clausen CF, Lahera V, Calderon J, Bolivar IC, Castillo VR, Gutierrez M, Carreno M, Oubina Mdel P, Cachefiero V, Lopez-Jaramillo P. The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol. 2010;139(1):32–41. https://doi.org/10.1016/j.ijcard.2008.09.005.
9. Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism. 2008;57(2):268–73. https://doi.org/10.1016/j.metabol.2007.09.011.
10. Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients. 2013;5(6):2019–27. https://doi.org/10.3390/nu5062019.
11. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2002;18:145–71. https://doi.org/10.1146/annurev.cellbio.16.1.
12. Butovcan D, Oboroneanu T, Cimpeanu C, Mironescu A, Halliga RE, Pinzariu AC, Lupusoru RV, Popescu E, Mocanu V. The involvement of Epidural adiposity and inflammation in Postoperative atrial Fibrillation - Immunohistochemical quantitative and qualitative assessment. REVCHIM (Bucharest). 2017;68(4):886–9.
13. Aarnouli V, Bulughiana S, Stoica B, Anieie E. Circulating Chemerin, oxidative stress, inflammation and insulin resistance in. Morbid Obesity Rev Chirin (Bucharest). 2017;68(5):1014–8.
14. Mihal BM, Petris AO, Ungureanu DA, Lacatuscu CM. Insulin resistance and adipokine levels correlate with early atherosclerosis - a study in prediabetic patients. Open Med (Wars). 2015;10(1):14–24. https://doi.org/10.1515/openmed-2015-0003.
15. Andersson DP, Eriksson Hogdlin D, Thorell A, Toft E, Qvisth V, Nasklund E, Thorne A, Wiren M, Lofgren P, Hoffstedt J, et al. Changes in subcutaneous fat cell volume and insulin sensitivity after weight loss. Diabetes Care. 2014;7(7):1831–6. https://doi.org/10.2337/dc13-2395.
16. Lonn M, Mehlig K, Bengtsson C, Lissner L. Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J. 2010;24(1):326–31. https://doi.org/10.1096/fj.09-13056.
17. Zúk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrich MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–23. https://doi.org/10.1089/1076376017502859.
18. Woo DH, Hwang HS, Shim JH. Comparison of adult stem cells derived from multiple stem cell niches. Biotechnol Lett. 2016;38(5):751–9. https://doi.org/10.1007/s10529-016-2050-2.
19. Beane OS, Fonseca VC, Cooper LL, Koren G, Darling EM. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One. 2014;9(12):e115963. https://doi.org/10.1371/journal.pone.0115963.
20. Russo V, Yu C, Belliveau P, Hamilton A, Flynn LE. Comparison of human adipose-derived stem cells isolated from subcutaneous, omental, and intrathoracic adipose tissue deposits for regenerative applications. Stem Cells Transl Med. 2013;2(2):206–17. https://doi.org/10.5966/sctm.2013-0125.
21. Mitterberger MC, Matteisich W, Zwerschke W. Bariatric surgery and diet-induced long-term caloric restriction protect subcutaneous adipose-derived stromal/progenitor cells and prolong their life span in formerly obese humans. Exp Gerontol. 2014;56:106–13. https://doi.org/10.1016/j.exger.2014.03.030.
22. Jeffery E, Churchill CD, Holtrup B, Colman L, Rodeheffer MS. Rapid depot-specific activation of adipocyte precursor cells at the onset of obesity. Nat Cell Biol. 2015;17(4):375–85. https://doi.org/10.1038/ncb3122.
23. Frazier TP, Gimble JM, Devay JW, Tucker HA, Chiu ES, Rowan BG. Body mass index affects proliferation and osteogenic differentiation of human subcutaneous adipose tissue-derived stem cells. BMC Cell Biol. 2013;14:34. https://doi.org/10.1186/1471-2121-14-34.
24. Isakson P, Hamrannstedt A, Gustafsson B, Smith U. Impaired prediapocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes. 2009;58(7):1550–7. https://doi.org/10.2337/db08-1770.
25. Oliva-Olivera W, Cohn-Araguez L, Lharnayani S, Clemente-Pastigo M, Torres JA, Bernal-Lopez MR, El Bekay R, Tinahones FJ. Adipogenic impairment of
adipose tissue-derived mesenchymal stem cells in subjects with metabolic syndrome: possible protective role of FGF2. J Clin Endocrinol Metab. 2017;102(2):478–87. https://doi.org/10.1210/jc.2016-2256.

26. Silva KR, Liechocki S, Camerio JR, Claudio-da-Silva C, Maya-Monteiro CM, Boroevic R, Baptista LS. Stromal-vascular fraction content and adipose stem cell behavior are altered in morbid obese and post bariatric surgery obese women. Stem Cell Res Ther. 2015;6:72. https://doi.org/10.1186/s13287-015-0029-x.

27. Louwen F, Ritter A, Kreis NN, Yuan J. Insight into the development of obesity: functional alterations of adipose-derived mesenchymal stem cells. Obes Rev. 2018;19(7):888–904. https://doi.org/10.1111/obr.12679.

28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.

29. Tsatsoulis A, Mantzaris MD, Bellou S, Andrikoula M. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment - an evolutionary perspective. Metabolism. 2013;62(5):622–33. https://doi.org/10.1016/j.metabol.2012.11.004.

30. McLaughlin T, Deng A, Yee G, Lamendola C, Reaven G, Tsao PS, Cushman SW, Sherman A. Inflammation in subcutaneous adipose tissue: relationship to adipocyte size. Diabetologia. 2010;53(2):369–77. https://doi.org/10.1007/s00125-009-1496-3.

31. Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome. Endocr Rev. 2013;34(Suppl 1):39–43.

32. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res. 2005;46(7):1369–79. https://doi.org/10.1194/jlr.M400373-JLR200.

33. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 2004;145(1):87–93. https://doi.org/10.1210/en.2003-1068.

34. Lee MJ, Fried SK. The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes. Int J Obes. 2014;38(9):1228–33. https://doi.org/10.1038/ijo.2014.6.

35. Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res. 1996;4(3):277–82.

36. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia. 2000;43(12):1498–506. https://doi.org/10.1007/s001250051560.

37. Pasarica M, Xie H, hymel D, Bray G, Greenway F, Ravussin E, Smith SR. Lower total adipocyte number but no evidence for small adipocyte depletion in patients with type 2 diabetes. Diabetes Care. 2009;32(5):900–2. https://doi.org/10.2337/dc08-2420.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.